Protara Therapeutics(NASDAQ) TARA

Protara Therapeutics, Inc. develops treatments for cancer and rare diseases. It helps people who have very few treatment options left. These therapies aim to fix medical problems using modern science.

What Protara is Developing

• TARA-002 for Bladder Cancer: Investigational cell therapy for cancer in the inner lining of the bladder; currently in Phase 2 trials for patients who do not respond to standard care.
• TARA-002 for Rare Cysts: Treatment for non-cancerous growths in the lymphatic system; targeting pediatric patients with specific cysts in the head and neck.
• Intravenous Choline Chloride: Nutrient replacement for patients who get all food and fluids through a vein; designed to prevent liver disease caused by nutrient deficiency.

Major Clinical Milestones

• Initiated a Phase 3 clinical trial for its lead nutritional candidate in Jan. 2026.
• Earned several special regulatory statuses from the U.S. Food and Drug Administration to speed up drug development.
• Reached an agreement with federal regulators in April 2024 on a specific path for its choline candidate.
• Redesigned the ADVANCED-3 trial in June 2026 to expand clinical research data for high-risk patients.

What Makes Protara Different

Protara uses a specific master cell bank to ensure its lead therapy is consistent and reliable. The company focuses on established biological paths to increase the chances of clinical success.

Tracking the Numbers

• Protara held $161.9 million in cash and securities as of June 30, 2026.
• Research and development expenses were $17.0 million for the three-month period ended June 30, 2026, up $6.2 million year over year.
• Net loss was $39.5 million for the six-month period ended June 30, 2026.
• The company reported an accumulated deficit of $341.9 million as of June 30, 2026.

Bottom Line

Protara has evolved from an early-stage company into a clinical-stage developer with multiple late-phase programs. Its focus on established scientific mechanisms across oncology and rare diseases provides a diverse path toward potential commercialization.